All In Biotech

Drug Trial Radar · NCT07700979

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

A Randomized, Double-blind, Multi-regional Phase 3 Study of Cadonilimab Combined With Chemotherapy Versus Chemotherapy in Combination With or Without Nivolumab for the First-line Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Sep 24, 2026

Primary completion

Aug 18, 2029

Study completion Aug 18, 2030

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Jul 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.

Conditions

  • Gastric / Gastroesophageal Junction Adenocarcinoma

Interventions

  • CadonilimabDrug

    Anti-PD-1/ CTLA-4 tetrameric bispecific antibody

  • CAPOX regimenDrug

    A combination treatment contains oxaliplatin and capecitabine

  • NivolumabDrug

    Anti-PD-1 monoclonal antibody

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Approximately up to 14months

Locations

25 sites in 4 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona · Not yet recruiting

  • UCLA Health

    Los Angeles, California · Not yet recruiting

  • Rocky Mountain Cancer Centers

    Denver, Colorado · Not yet recruiting

  • Yale School of Medicine

    New Haven, Connecticut · Not yet recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Not yet recruiting

  • Henry Ford Health

    Detroit, Michigan · Not yet recruiting

  • Mount Sinai

    New York, New York · Not yet recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Not yet recruiting

  • Oregon Health and Science University

    Portland, Oregon · Not yet recruiting

  • Sarah Cannon Research Institute (SCRI) - Oncology Partners

    Nashville, Tennessee · Not yet recruiting

  • Baylor Scott & White Health

    Dallas, Texas · Not yet recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Not yet recruiting

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin · Not yet recruiting

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China · Not yet recruiting

  • Peking University Cancer Hospital, Gastrointestinal Cancer Center I

    Beijing, China · Recruiting

  • Peking University Cancer Hospital, Gastrointestinal Oncology

    Beijing, China · Not yet recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, China · Not yet recruiting

  • Zhongshan Hospital Fudan University

    Shanghai, China · Not yet recruiting

  • University Cancer Center Frankfurt

    Frankfurt, Germany · Not yet recruiting

  • Universitätsmedizin der Johannes Gutenberg-Universität

    Mainz, Germany · Not yet recruiting

  • Univerity Marburg

    Marburg, Germany · Not yet recruiting

  • Universitaetsklinikum Essen

    Essen, North Rhine-Westphalia, Germany · Not yet recruiting

  • Pratia MCM Kraków

    Krakow, Poland · Not yet recruiting

  • Pratia Poznań

    Poznan, Poland · Not yet recruiting

  • Narodowy Instytut Onkologii-im. Marii Sklodowskiej Curie Panstwowy Instytut Badawczy - w Warszawie

    Warsaw, Poland · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.